Pharmacia To Launch Parecoxib With Zyvox Sales Force: No Partner Needed
Executive Summary
Pharmacia plans to launch the injectable COX-2 inhibitor parecoxib using the hospital sales force that launched the antibiotic Zyvox (linezolid), Global Business Management President Carrie Cox said during an Oct. 30 earnings conference call.
You may also be interested in...
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.
Vioxx
In September, rofecoxib had a 49.9% of new prescriptions in the COX-2 inhibitor market, Merck says